Blog
RSS FeedPosted by Michael Wonder on 14 Nov 2016
Too much chemotherapy
10 November 2016 - People with cancer are living longer now than 40 years ago. This is clearly good news. But ...
Posted by Michael Wonder on 14 Nov 2016
Medibank’s Drummond: prostheses savings ‘just the start’
10 November 2016 - Medibank chief Craig Drummond has warned market conditions will continue to be challenged as he flags ...
Posted by Michael Wonder on 14 Nov 2016
Graeme Samuel urges cuts to price-fixing prostheses list
8 November 2016 - A top consultant to the federal government on health reform, former competition boss Graeme Samuel, has ...
Posted by Michael Wonder on 14 Nov 2016
Decision to list enzyme replacement therapies for some rare disorders
11 November 2016 - PHARMAC is pleased to announce the approval of an agreement with Sanofi-Aventis for the listing of ...
Posted by Michael Wonder on 13 Nov 2016
SMC - November 2016 decisions
7 November 2016 - Five new medicines accepted for routine use in Scotland. ...
Posted by Michael Wonder on 13 Nov 2016
Life-extending breast cancer drug approved by NICE in draft guidance
3 November 2016 - People with advanced breast cancer are set to benefit from a life-extending drug as NICE says it ...
Posted by Michael Wonder on 13 Nov 2016
Price cuts pave the way for routine access to breast and lung cancer drugs
10 November 2016 - People with breast cancer and lung cancer will have routine access to two life-extending treatments after the ...
Posted by Michael Wonder on 13 Nov 2016
Additional public summary documents from the PBAC July 2016 meeting
11 November 2016 - Additional public summary documents from the PBAC July 2016 meeting are now available. ...
Posted by Michael Wonder on 06 Nov 2016
MAESTrO Daily maintenance
6 November 2016 - MAESTrO Daily is need of some urgent maintenance so there will be no issues this week. ...
Posted by Michael Wonder on 02 Nov 2016
Confounding by indication in clinical research
1 November 2016 - In the assessment of the effect of a treatment or potential risk factor—termed an exposure—on a patient ...
Posted by Michael Wonder on 02 Nov 2016
New expensive anti-cancer agents: which role is played by quality-adjusted life-years in the selection of a specific treatment?
1 November 2016 - Koczwara et al. emphasise that dissemination and implementation science should broaden its reach beyond its current geographic ...
Posted by Michael Wonder on 02 Nov 2016
Jardiance recommended by CADTH for use by patients with type 2 diabetes mellitus at high risk of cardiovascular disease
26 October 2016 - CADTH publishes final recommendation on prevention of cardiovascular mortality in type 2 diabetes mellitus. ...
Posted by Michael Wonder on 01 Nov 2016
NICE issues draft guidance on the use of ixekizumab
1 November 2016 - NICE has issued draft guidance on the use of Taltz (ixekizumab) for the treatment of patients ...
Posted by Michael Wonder on 01 Nov 2016
Head and neck cancer drug is not cost-effective
1 November 2016 - Cetuximab is not value for money says NICE in new draft guidance. ...
Posted by Michael Wonder on 01 Nov 2016
ACCC issues fresh warning to health insurance firms over failures
31 October 2016 - Australian insurance groups have been put on notice by the consumer watchdog for not properly notifying ...